16:39 IST
NSE
Regulatory Approval
Natco Pharma Regulatory Approval
Natco Pharma received tentative U.S. FDA approval for Olaparib tablets. The reference drug Lynparza reported USD 1.4 billion in U.S. sales.
Natco Pharma Ltd
- Share price
- ₹810.10
- Market cap
- ₹15,892 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 13.9×Sector 47.3×
- Promoter holding
- 49.42%+0.00% QoQ
- FII holding
- 16.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Earnings Call 3Capital Structure Change 3Board Meeting Outcome 3Board Meeting Date 3Fund Raise 2Acquisition 2Regulatory Approval 1Promoter Selling (Off-Market) 1Other Announcement 1Merger & Restructuring 1Legal & Regulatory 1Financial Results 1Dividend 1Business Update 1Annual Report 1Annual General Meeting 1
Time
1 announcement with these filters